MURRAY HILL, N.J.--(BUSINESS WIRE)--C. R. Bard, Inc. (NYSE:BCR) announced today the presentation of the 12-month results from the Lutonix® Global Real-World Registry at the Transcatheter Cardiovascular Therapeutics (TCT) 2015 meeting. These results come just months after publication in the New England Journal of Medicine of the 1-year data from the Lutonix® 035 Drug Coated Balloon (DCB) Catheter pivotal, randomized LEVANT 2 trial.
Help employers find you! Check out all the jobs and post your resume.
